SCHEMBL981799

SCHEMBL981799

O=C(Cc1ccc2[nH]cnc2c1)N1CCC(c2cc(Cl)ccc2Cl)=N1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.48
ORAI1 Q96D31 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 1/20 0.35
TYMS P04818 1/20 0.35
LMNA P02545 3/20 0.34
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ECE2 P0DPD6 1/20 0.33
NAMPT P43490 1/20 0.33
QPCT Q16769 1/20 0.32
P2RY14 Q15391 1/20 0.32
PPARG P37231 1/20 0.32
PPARD Q03181 1/20 0.32
PPARA Q07869 1/20 0.32
OPRK1 P41145 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
MEN1 O00255 1/20 0.32
FNTA P49354 1/20 0.32
FNTB P49356 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL979465 0.91 MET (0.41) METORAI1L3MBTL1POLBTYMS
SCHEMBL982528 0.87 PGR (0.41) METL3MBTL1POLBTYMSLMNA
SCHEMBL17004375 0.85 ORAI1 (0.39) METORAI1TYMSLMNASMN1; SMN2
SCHEMBL981952 0.83 PARP1 (0.34) METTYMSECE2
SCHEMBL982372 0.81 MET (0.50) METORAI1LMNAKMT2ASMN1; SMN2
SCHEMBL4628246 0.81 ALDH1A1 (0.41) METPOLBTYMSKMT2ASMN1; SMN2
SCHEMBL980139 0.79 SMN1; SMN2 (0.35) POLBTYMSSMN1; SMN2ECE2NAMPT
SCHEMBL981997 0.79 ALDH1A1 (0.38) METTYMSSMN1; SMN2ECE2NAMPT
SCHEMBL979214 0.77 GRM5 (0.38) SMN1; SMN2
SCHEMBL983930 0.77 MET (0.58) METORAI1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 MET 1/4885ORAI1 4824/4885L3MBTL1 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.